Refractory Myasthenia Gravis: New Immune Marker Predicts Treatment Response
Scientists at the University of Manchester have identified a distinct immune marker in patients with treatment-resistant myasthenia gravis (MG), a debilitating autoimmune disease, potentially paving the way for more personalized therapies. The research, published in the journal Med, reveals a unique pattern of immune dysregulation in individuals who fail to respond to standard treatments.
Myasthenia gravis occurs when the immune system mistakenly attacks the neuromuscular junction, disrupting communication between nerves and muscles, leading to muscle weakness. While many patients experience relief with current therapies, a significant subset develops refractory MG, a severe form unresponsive to conventional treatment. Currently, clinicians lack reliable tools to predict which patients will fall into this category.
The University of Manchester team analyzed blood samples from individuals living with MG, comparing them to those of healthy volunteers. Their investigation revealed that patients with refractory MG exhibited an overactive adaptive immune response, characterized by elevated levels of memory B cells. Simultaneously, the study found a marked reduction in regulatory T cells, which normally function to suppress excessive inflammation, effectively weakening the body’s natural “braking system” against autoimmune attacks.
Beyond the adaptive immune system, researchers too observed alterations in the innate immune response. These included decreased numbers of dendritic cells and increased monocytes, alongside heightened activity of the complement system – a cascade of proteins that contributes to inflammation and cell damage at the neuromuscular junction. These findings collectively point to ongoing immune-mediated damage.
The study also examined a subset of refractory MG patients undergoing treatment with rituximab, a drug designed to deplete B cells. While rituximab successfully reduced B cell counts in all patients, clinical improvement was not universal. Researchers discovered that those who did not respond to rituximab possessed a form of the disease driven by long-lived plasma cells and particularly high complement activity. This suggests that these patients might benefit more from therapies specifically targeting the complement pathway, rather than solely focusing on B cell depletion.
“For patients whose symptoms do not improve with existing treatments, the lack of clear answers can be incredibly frustrating,” said Dr. Katy Dodd, Neurology Consultant at Manchester Centre for Clinical Neuroscience. “Our findings aid explain why some therapies work for certain patients but not others, and point toward more personalised approaches that could improve outcomes in the future.”
Dr. Madhvi Menon, UKRI Future Leaders Fellow at the Lydia Becker Institute of Immunology and Inflammation and lead author of the paper, added, “Our study identifies a distinct immune signature associated with treatment-resistant myasthenia gravis. Understanding these immune differences brings us closer to predicting how patients will respond to therapy and to developing more targeted, personalised treatment approaches.”
Recent research indicates the myasthenia gravis market is projected to reach $10.3 billion across seven major markets by 2034, reflecting the growing necessitate for effective treatments. Another study highlighted the potential of tofacitinib, an arthritis drug, as a treatment option for hard-to-treat MG, while a case report detailed the use of eculizumab in highly active MG complicated by severe infections.